Buscar en
Revista Colombiana de Cardiología
Toda la web
Inicio Revista Colombiana de Cardiología Diferencias de género en el tratamiento de la falla cardíaca
Información de la revista
Vol. 21. Núm. 1.
Páginas 27-32 (Enero - Febrero 2014)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 21. Núm. 1.
Páginas 27-32 (Enero - Febrero 2014)
Open Access
Diferencias de género en el tratamiento de la falla cardíaca
Gender differences in the treatment of heart failure
Visitas
2462
Clara Saldarriaga1,2,3,
Autor para correspondencia
clarais@une.net.co

Correspondencia: Clínica CardioVID. Calle 78 B # 75-21. Teléfono: (571) 4 45 40 00. Medellín, Colombia.
, Nathalia González1, Alejandra Ávila3
1 Clínica CardioVID. Medellín, Colombia
2 Universidad de Antioquia. Medellín, Colombia
3 Universidad Pontificia Bolivariana. Medellín, Colombia
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Introducción

la falla cardíaca representa un problema creciente de salud con una alta prevalencia en el sexo femenino; sin embargo, no se han reportado estudios en población de mujeres latinoamericanas que permitan identificar si existen diferencias de género tanto en la presentación clínica como en el tratamiento de esta patología.

Objetivo

evaluar si existen diferencias tanto en las características clínicas y epidemiológicas como en el manejo farmacológico en función del género, en una serie de pacientes con falla cardíaca atendidos en un centro de referencia cardiovascular en Colombia.

Metodología

estudio observacional, descriptivo, que evaluó a todos los pacientes hospitalizados por síndrome de falla cardiaca como diagnóstico principal durante julio de 2009 y julio de 2010 en un centro de referencia cardiovascular colombiano.

Resultados

se incluyeron 204 pacientes, 36,7% de sexo femenino, cuya edad promedio fue mayor en las mujeres; la fracción de eyección promedio fue similar. Las mujeres tenían falla renal con mayor frecuencia. Se encontró menor uso de betabloqueadores, así como de implante de cardiodesfibrilador.

Conclusión

para la población estudiada se encontró que existen diferencias entre ambos sexos tanto en las variables demográficas como clínicas. A pesar de presentar mayores comorbilidades, las mujeres con falla cardiaca reciben con menor frecuencia terapias como los betabloqueadores y el cardiodesfibrilador implantable que han demostrado disminuir la mortalidad. Es necesario ampliar el conocimiento de las diferencias de género mediante la creación de un registro multicéntrico latinoamericano que permita incidir en la toma de decisiones clínicas propias para la región.

Palabras clave:
falla cardiaca
mujer
epidemiología
Introduction

heart failure is a growing health problem with a high prevalence in females; however, there are no studies reporting if there are gender differences in both the clinical presentation and treatment of this pathology in Latin-American women.

Objective

to assess whether there are differences in both clinical and epidemiological characteristics and pharmacological management in terms of gender, in a series of patients with heart failure treated at a cardiovascular referral center in Colombia.

Methods

observational descriptive study, which evaluated all patients hospitalized for heart failure syndrome as the primary diagnosis between July 2009 and July 2010 in a Colombian cardiovascular referral center.

Results

204 patients were included, 36.7% were females. Mean age was higher in women; the mean ejection fraction was similar in both groups. Women had more frequently renal failure. Lower use of beta blockers, as well as of cardiac defibrillator implant was found in women.

Conclusion

in this study population we found that there are gender differences in both demographic and clinical variables. Despite presenting more comorbidities, women with heart failure less frequently receive the therapies that have shown to reduce mortality such as beta blockers and implantable cardioverter defibrillator. It is necessary to expand our knowledge of gender differences through the creation of a Latin American multicenter registry that effectively enable to influence the clinical decision making proper for the region.

Key words:
cardiac failure
woman
epidemiology
El Texto completo está disponible en PDF
Bibliografía
[1.]
H. Grisales, G.S. Bedoya.
Change in life expectancy in connection with three large groups of causes of death in Medellin Colombia, between 1989-1991 and 1994-1996.
Pan American Journal of Public Health, 12 (2002), pp. 305-312
[2.]
S. Allender, P. Scarborough, V. Peto.
Coronary heart disease statistics 2007 edition British heart foundation health promotion research group.
BHF, (2007 p), pp. 35-50
[3.]
T. Thom, N. Haase, W. Rosamond, V.J. Howard, J. Rumsfeld, T. Manolio, et al.
Heart disease and stroke statistics— 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation, 113 (2006), pp. e85-e151
[4.]
D.H. Silber.
Heart failure in women.
Curr Womens Health Rep, 3 (2003), pp. 104-109
[5.]
S.C. Gan, S.K. Beaver, P.M. Houck, R.F. MacLehose, H.W. Lawson, L. Chan, et al.
Treatment of acute myocardial infarction and 30-day mortality among women and men.
N Engl J Med, 343 (2000), pp. 8-15
[6.]
N.M. Buderer.
Statistical methodology: I Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity.
Acad Emerg Med, 3 (1996), pp. 895-900
[7.]
R.V. Carlson, K.M. Boyd, D.J. Webb.
The revision of the Declaration of Helsinki: past, present and future.
Br J ClinPharmacol, 57 (2004), pp. 695-713
[8.]
M. Galvao, J. Kalman, T. DeMarco, G.C. Fonarow, C. Galvin, J.K. Ghali, et al.
Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
J Card Fail, 12 (2006), pp. 100-107
[9.]
C.N. Bairey Merz, L.J. Shaw, S.E. Reis, V. Bittner, S.F. Kelsey, M. Olson, for the WISE Investigators, et al.
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease.
J Am Coll Cardiol, 47 (2006), pp. S21-S29
[10.]
V.P. Harjola, F. Follath, M.S. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, et al.
Gender related differences in patients presenting with acute heart failure Results from Results from Euro Heart Failure Survey II.
Eur J Heart Fail, 10 (2008), pp. 140-148
[11.]
E. O’Meara, T. Clayton, M.B. McEntegart, J.J. McMurray, I.L. Piña, C.B. Granger, et al.
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation, 115 (2007), pp. 3111-3120
[12.]
K. Kuulasmaa, H. Tunstall-Pedoe, A. Dobson, S. Fortmann, S. Sans, H. Tolonen, et al.
Estimation of contribution of changes in classic risk factors to trends incoronaryevent rates across the WHO MONICA Project populations.
Lancet, 355 (2000), pp. 675-687
[13.]
H. Schulte, A. von Eckardstein, P. Cullen, G. Assmann.
Obesity and cardiovascular risk.
Herz, 26 (2001), pp. 170-177
[14.]
T.R. Wessel, C.B. Arant, M.B. Olson, B.D. Johnson, S.E. Reis, B.L. Sharaf, et al.
Relationship of physical fitness vs. body mass index with coronary artery disease and cardiovascular events in women.
JAMA, 292 (2004), pp. 1179-1187
[15.]
G.C. Fonarow, J.T. Heywood, P.A. Heidenreich, M. Lopatin, C.W. Yancy.
ADHERE Scientific Advisory Committee and Investigators Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE).
Am Heart J, 153 (2007), pp. 1021-1028
[16.]
K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, Poole- Wilson, et al.
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).
Eur J Heart Fail, 10 (2008), pp. 933-989
[17.]
N. Bairey Merz, R.O. Bonow, G. Sopko, R.S. Balaban, R.O. Cannon, D. Gordon, National Heart, Lung and Blood Institute; American College of Cardiology Foundation, et al.
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart Lung and Blood Institute workshop: October 2-4 2002 executive summary.
Circulation, 109 (2004), pp. 805-807
[18.]
L. Cubillos-Garzón, J. Casas, C. Morillo, L. Bautista.
Congestive heart failure in Latin America: the next epidemic.
Am Heart J, 147 (2004), pp. 412-417
[19.]
E.M. Hsich, I.L. Piña.
Heart failure in women: a need for prospective data.
J Am Coll Cardiol, 54 (2009), pp. 491-498
[20.]
T. Simon, M. Mary-Krause, C. Funck-Brentano, P. Jaillon.
Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II).
Circulation, 103 (2001), pp. 375-380
[21.]
M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, for the U.S. Carvedilol Heart Failure Study Group, et al.
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
N Engl J Med, 334 (1996), pp. 1349-1355
[22.]
S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats, et al.
2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol, 53 (2009), pp. e1-e90
[23.]
The, CONSENSUS., Trial Study Group,.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
N Engl J Med, 316 (1987), pp. 1429-1435
[24.]
R. Garg, S. Yusuf, for the Collaborative Group on ACE Inhibitor Trials.
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
JAMA, 273 (1995), pp. 1450-1456
[25.]
P.G. Shekelle, M.W. Rich, S.C. Morton, C.S. Atkinson, W. Tu, M. Maglione, et al.
Efficacy of angiotensin converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis.
J Am Coll Cardiol, 41 (2003), pp. 1529-1538
[26.]
J.B. Young, M.E. Dunlap, M.A. Pfeffer, J.L. Probstfield, A. Cohen-Solal, R. Dietz, et al.
Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Circulation, 110 (2004), pp. 2618-2626
[27.]
M.R. Bristow, L.A. Saxon, J. Boehmer, S. Krueger, D.A. Kass, T. De Marco, et al.
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
N Engl J Med, 350 (2004), pp. 2140-2150
[28.]
G.H. Bardy, K.L. Lee, D.B. Mark, J.E. Poole, D.L. Packer, R. Boineau, et al.
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
N Engl J Med, 352 (2005), pp. 225-237
Copyright © 2014. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular
Opciones de artículo
Herramientas